The U.S. Food and Drug Administration gave a green light to Eli Lilly's donanemab for patients with early Alzheimer's, making it the second approved drug for slowing the progress of the brain-wasting disease.
U.S. approves 2nd Alzheimer’s drug to modestly slow disease